Actinic Keratosis News and Research

RSS
Actinic keratosis, also known as solar keratosis, is a dry, scaly patch of skin that presents as a result of chronic exposure to sunlight. Most people with the condition do not report significant symptoms, although the condition can progress to a type of skin cancer, squamous cell carcinoma, in severe cases without treatment.
MEDA seeks marketing authorization for Zyclara in Europe

MEDA seeks marketing authorization for Zyclara in Europe

FDA approves Taro's Imiquimod Cream ANDA

FDA approves Taro's Imiquimod Cream ANDA

LEO selects Veeva CRM to support its rapidly growing New Markets Europe region

LEO selects Veeva CRM to support its rapidly growing New Markets Europe region

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Solta Medical's Fraxel re:store Dual system for actinic keratosis receives FDA 510(k) clearance

Solta Medical's Fraxel re:store Dual system for actinic keratosis receives FDA 510(k) clearance

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference

PhotoMedex receives multi-million dollar order from AMICO Group to purchase XTRAC laser systems

PhotoMedex receives multi-million dollar order from AMICO Group to purchase XTRAC laser systems

SurModics licenses biodegradable polymer implant technology to Clinuvel

SurModics licenses biodegradable polymer implant technology to Clinuvel

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

DUSA Pharmaceuticals first-quarter total product revenues up 22%

DUSA Pharmaceuticals first-quarter total product revenues up 22%

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

Skinvisible obtains Korean patent for polymer delivery system

Skinvisible obtains Korean patent for polymer delivery system

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting

LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting

Meda publishes 2009 year-end report

Meda publishes 2009 year-end report

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.